Venus Pharma secured marketing authorisation from France
The authorisation is for meropenem, a generic broad spectrum antibiotic injectable.
Chandigarh, August 20, 2013: Venus Pharma GmbH, a subsidiary of Venus Remedies has received marketing authorisation approval from France for meropenem, a generic broad spectrum antibiotic injectable. The company has also signed a non-exclusive marketing rights deal with generic drug maker Mylan to sell meropenem in France.
It is believed that the company is well poised to gain maximum share in the US$ 270 million meropenem market in the EU in the coming times. It may be noted here that meropenem is an off-patented generic broad spectrum anti- bacterial agent of carbapenem family, which fights diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.
The company generated business worth Euro 5 million from meropenem exports in 2012-13 and the figure is expected to double by the end of this year. The company also plans to capture the meropenem market in other markets like Australia, Spain, Switzerland, South Africa, Malaysia and Gulf Central Committee (GCC) countries.